Effect of lamivudine treatment on plasma levels of transforming growth factor &beta;1, tissue inhibitor of metalloproteinases-1 and metalloproteinase-1 in patients with chronic hepatitis B

doi:10.3748/wjg.v10.i18.2661

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 10, Issue 18

This Article

Citation of this article

Corresponding Author of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (2786)

All Articles published online

The chart showing PDF series, HTML series, Figures (1-4) series, Tables (1-5) series.

Item

Count

PDF

280

HTML

2183

Figures (1-4)

150

Tables (1-5)

173

Sum=2786

Sep 15, 2004 (publication date) through Jul 22, 2024

Times Cited of This Article

Times Cited (10)

Journal Information of This Article

Publication Name

World Journal of Gastroenterology

ISSN

1007-9327

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Viral Hepatitis

World J Gastroenterol. Sep 15, 2004; 10(18): 2661-2665
Published online Sep 15, 2004. doi: 10.3748/wjg.v10.i18.2661

Table 2 Correlation expressed by r-value and its significance between analyzed biochemical indices and TGF-β₁, TIMP-1 or MMP-1 in chronic hepatitis B patients treated with lamivudine

	mean ± SE	TGF-β₁	TIMP-1	MMP-1
Bil (mg%)	1.02 ± 0.06	0.049	0.119	-0.059
ALT (U/L)	74.50 ± 5.9	0.201^a	0.247^a	0.005
AST (U/L)	60.10 ± 5.2	0.244^a	0.269^a	-0.029
ALP (U/L)	96.10 ± 3.8	0.114	0.295^a	-0.071
GGT (U/L)	47.70 ± 4.9	0.062	0.247^a	-0.102
PI (%)	87.30 ± 1.5	-0.109	0.006	-0.065

Bil: bilirubin; ALT: alanine aminotransferase; AST: aspartate aminotransferase; ALP: alkaline phosphatase; GGT: gamma glutamyltranspeptidase; PI: prothrombin index.

^aP < 0.05 vs other groups.

Citation: Flisiak R, Al-Kadasi H, Jaroszewicz J, Prokopowicz D, Flisiak I. Effect of lamivudine treatment on plasma levels of transforming growth factor β₁, tissue inhibitor of metalloproteinases-1 and metalloproteinase-1 in patients with chronic hepatitis B. World J Gastroenterol 2004; 10(18): 2661-2665
URL: https://www.wjgnet.com/1007-9327/full/v10/i18/2661.htm
DOI: https://dx.doi.org/10.3748/wjg.v10.i18.2661